首页> 外文期刊>Journal of Clinical Medicine and Research >Comparative effect of albendazole and diethylcarbamazine in the treatment of toxocariasis in children from Sri Lanka: A preliminary study
【24h】

Comparative effect of albendazole and diethylcarbamazine in the treatment of toxocariasis in children from Sri Lanka: A preliminary study

机译:阿苯达唑和二乙基卡巴他嗪治疗斯里兰卡儿童弓形虫病的比较效果:初步研究

获取原文
           

摘要

Toxocariasis is a helminthozoonotic disease with significant morbidity. Diverse medications and different regimens are used in its treatment. Toxocariasis has a significant prevalence among Sri Lankan children, yet its treatment has not been evaluated. This was a preliminary study to determine the impact of ALB and DEC on the levels of anti-Toxocara?antibodies and eosinophil count in 19 children who were tested positive for?Toxocariasis,?using the Microwell Serum Elisa Kit. Of these children, 10 were treated with ALB and 9 with DEC. Treatment response was defined as a significant reduction in the eosinophil count and anti-Toxocara?antibody levels from the baseline level following treatment. There was a significant reduction in the anti-Toxocara?antibodies with ALB as compared to DEC. Both drugs also showed a significant reduction of the eosinophil count post treatment as compared to baseline. The ALB regimen that was used of shorter duration course with a slightly higher dose as compared to other published literature. The dose was well tolerated and its compliance was good. Considering efficacy and acceptability, ALB (50 mg/kg/day) in 2 divided doses for 3 days is effective for treatment of toxocariasis in Sri Lankan children.
机译:弓形虫病是一种具有明显发病率的蠕虫病。治疗中使用了多种药物和不同的治疗方案。弓形虫病在斯里兰卡儿童中普遍流行,但尚未对其治疗进行评估。这是一项初步研究,目的是确定使用Microwell血清酶联免疫试剂盒对19名被测试为“弓形虫病”呈阳性的儿童的ALB和DEC对抗弓形虫抗体水平和嗜酸性粒细胞计数的影响。在这些儿童中,有10名接受了ALB治疗,而9名接受了DEC治疗。治疗反应定义为治疗后嗜酸性粒细胞计数和抗弓形虫抗体水平从基线水平显着降低。与DEC相比,ALB的抗弓形虫抗体显着减少。与基线相比,两种药物还显示治疗后的嗜酸性粒细胞计数显着减少。与其他已发表的文献相比,所用的ALB方案疗程较短,剂量稍高。剂量耐受良好,依从性良好。考虑到疗效和可接受性,ALB(50 mg / kg /天)分两次服用,持续3天可有效治疗斯里兰卡儿童弓形虫病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号